Inicio › Cáncer de mama triple negativo › Nueva York › New York City
Ensayos clínicos de Cáncer de mama triple negativo en New York City, NY
31 estudios para Cáncer de mama triple negativo buscan participantes en centros de New York City y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Icahn School of Medicine at Mount Sinai, New York
- y 2 más
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
ReclutandoFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Study of AVZO-021 in Patients With Advanced Solid Tumors
ReclutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
ReclutandoEstudio observacional
- NYU Langone Medical Center, New York
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ReclutandoFase 3
- Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
ReclutandoFase 3
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
- Icahn School of Medicine at Mount Sinai ( Site 0123), New York
- Memorial Sloan Kettering Cancer Center ( Site 0067), New York
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
ReclutandoFase 1
- Memorial Sloan Kettering Cancer Center Head Neck Services, New York
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
ReclutandoFase 1
- Icahn School of Medicine at Mt. Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
ReclutandoFase 1
- Memorial Sloan Kettering Cancer Center (All protocol activites), New York
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
ReclutandoFase 1/2
- Mount Sinai, New York
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
ReclutandoFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
ReclutandoFase 2
- NYP/Weill Cornell Medical Center, New York
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
ReclutandoFase 3
- Laura and Isaac Perlmutter Cancer Canter, New York
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
ReclutandoFase 1
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
ReclutandoFase 2
- Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
ReclutandoFase 2/3
- Memorial Sloan Kettering Cancer Center, New York
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Memorial Sloan Kettering Cancer Center 53rd street., New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
ReclutandoFase 1/2
- New York University Langone Health, New York
- ICHAN School of Medicine at Mount Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LY4175408 in Participants With Advanced Cancer
ReclutandoFase 1
- Columbia University, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
ReclutandoFase 1
- New York Medicine-New York-Presbyterian Hospital, New York
- Montefiore Medical Center - Montefiore Hospital, New York
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
ReclutandoFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
ReclutandoFase 1 temprana
- Mount Sinai Health System, New York
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
ReclutandoFase 2
- Laura and Isaac Perlmutter Cancer Center / NYU Langone Health, New York
- Columbia University Medical Center, New York
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
ReclutandoFase 1/2
- NYU Langone perimutter Cancer Center, New York
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
ReclutandoFase 1
- Memorial Sloan Kettering Cancer Center, New York
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
ReclutandoFase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
ReclutandoFase 2
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
ReclutandoFase 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
ReclutandoFase 1/2
- NYU Langone Health, New York
Ensayos de Cáncer de mama triple negativo en otras ciudades
- Houston, TX42 estudios
- Nashville, TN28 estudios
- Los Angeles, CA27 estudios
- Boston, MA26 estudios
- San Antonio, TX23 estudios
- St. Louis, MO21 estudios
- Arlington, VA20 estudios
- Atlanta, GA20 estudios
- Dallas, TX18 estudios
- Chicago, IL16 estudios
- Columbus, OH16 estudios
- Grand Rapids, MI15 estudios
Otros estudios en New York City
- Cáncer de seno136 estudios
- Cáncer de pulmón de células no pequeñas121 estudios
- Cáncer (todos los tipos)109 estudios
- Cáncer de próstata103 estudios
- Cáncer metastásico93 estudios
- Cáncer del colon y del recto78 estudios
- Cáncer de ovario69 estudios
- Cáncer de pulmón60 estudios
- Mieloma múltiple60 estudios
- Cáncer de páncreas60 estudios
- Cáncer de endometrio52 estudios
- Leucemia mielógena aguda51 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.